GSK sues Pfizer over patents for RSV vaccine
GlaxoSmithKline sued Pfizer on Wednesday over patent infringement, alleging the US drugmaker's RSV vaccine steals key elements of the British company's version.
Aug 2, 2023
0
21
MeSH tree: C01.748.099.135
GlaxoSmithKline sued Pfizer on Wednesday over patent infringement, alleging the US drugmaker's RSV vaccine steals key elements of the British company's version.
Aug 2, 2023
0
21
Telethon Kids Institute study has suggested the seasonal flu vaccine for children could also protect them from respiratory syncytial virus (RSV), with the dual benefit easing pressure on hospitals.
Jul 27, 2023
0
39
This winter, we're having to get our heads around another respiratory virus—RSV.
Jul 26, 2023
0
34
Europe's drug watchdog on Friday approved the world's first vaccine for infants and those over 60 against the Respiratory Syncytial Virus, a major cause of hospitalization on the continent, the Amsterdam-based agency said.
Jul 21, 2023
0
50
The 2023 flu season is shaping up to be like the influenza season of 2019—the largest on record in Australia.
Jul 19, 2023
0
36
New research from QIMR Berghofer has shown that a high-fiber diet in breastfeeding mothers could potentially protect infants from serious respiratory conditions such as asthma.
Jul 19, 2023
0
87
Parents now have a new long-acting drug to protect their children against respiratory syncytial virus (RSV), a common germ that hospitalizes as many as 3% of children under the age of 1 in the United States each year.
Jul 18, 2023
0
83
As the Centers for Disease Control and Prevention (CDC) determines whether to approve a vaccine against RSV for adults 60 and older, a new survey from the Annenberg Public Policy Center finds that the American public is ill-informed ...
Jun 21, 2023
0
33
A new AI algorithm developed at EPFL and University Hospital Geneva (HUG) will power an intelligent stethoscope called Pneumoscope with the potential to improve the management of respiratory disease in low-resource and remote ...
Jun 12, 2023
0
56
The European Commission has followed the United States in approving the world's first vaccine for the Respiratory Syncytial Virus, to be used by adults aged 60 and over, its maker GlaxoSmithKline said Wednesday.
Jun 7, 2023
0
49